Cellular Dynamics International Announces Agreement With AstraZeneca PLC on Use of iPSC-derived Human Cells in Drug Discovery Research

MADISON, Wis., Jan. 3, 2013 /PRNewswire/ -- Cellular Dynamics International, Inc. (CDI) today announced a Center of Excellence agreement with AstraZeneca to accelerate the pace of drug discovery throu…

---

Alkermes plc Expands CNS Pipeline and Announces Positive Results From Phase 1 Study of ALKS 3831, a Novel Antipsychotic Therapy for the Treatment of Schizophrenia

DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced positive topline results from a phase 1 study of its new antipsychotic candidate, ALKS 3831, a combination of a proprietary drug mo…

---

Alkermes plc???s Corporate Presentation to be Webcast at the 31st Annual Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the 31st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 8, 2013, at 8:00 a.m. PST (11:00…

---

Alkermes plc Announces Notice of Allowance of Key U.S. Patent for Aripiprazole Lauroxil, a New Schizophrenia Drug Candidate

DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application 12/823,007,…

---